PCI Biotech Holding ASA
PCI Biotech - release of the RNA Therapeutics Virtual Conference presentation
Oslo (Norway), 10 February 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today released the fimaNAc focused presentation for the 12th Annual RNA Therapeutics Virtual Conference, a UK based online event taking place February 10-11, 2021. The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies, oligonucleotide delivery, therapeutic applications and future trends and innovations. PCI Biotech is also a sponsor of the event.
Today, Wednesday February 10 2021, at 13:10pm (CET) Dr. Anders Høgset, CSO, will present an overview of PCI Biotech’s proprietary platform technology, focusing on the delivery of RNA molecules, including the most recent data on the use of the fimaNAc delivery technology in the exciting field of RNA based therapies.
Per Walday, CEO of PCI Biotech, comments: Encouraging collaborative preclinical results have recently been achieved with the fimaNAc technology and we are very pleased to be able to share these data now. The rapid development progress of mRNA-based vaccines against Covid-19 has generated much attention to the potential of nucleic acid therapeutics generally, and mRNA particularly. The results with fimaNAc suggests that this technology provides an appealing intracellular delivery solution for certain applications within this class of therapeutics.
An online recording of the full presentation held by Dr Høgset will be made available on PCI Biotech’s website (www.pcibiotech.com) under "Scientific publications & presentations" after the event.
Per Walday, CEO
Mobile: +47 917 93 429
About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
For further information, please visit: www.pcibiotech.com
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Calibre Mining Corp.25.2.2021 00:31:29 CET | Press release
Calibre Exceeds High End of 2020 Production Guidance With 136,009 Ounces and Beats Low End of All-in Sustaining Cost Guidance at $1,043 Per Ounce
Adevinta ASA24.2.2021 23:18:27 CET | Press release
Adevinta ASA (ADE) - Adevinta further optimises its portfolio by divesting Yapo in Chile
Tenaris S.A.24.2.2021 23:00:26 CET | Press release
Tenaris Announces 2020 Fourth Quarter and Annual Results
Colliers International Group Inc.24.2.2021 22:31:35 CET | Press release
Colliers recognized as a 2021 Global Outsourcing 100® company
HEINEKEN NV24.2.2021 22:07:54 CET | Press release
HEINEKEN, The Coca-Cola Company and the Coca-Cola System in Brazil announce redesigned distribution partnership
Aalberts N.V.24.2.2021 21:16:30 CET | Press release
Aalberts N.V.: Aalberts accelerates strategy and continues investments and innovations; solid and resilient performance with strong free cash flow
Release24.2.2021 20:21:48 CET | Press release
Scatec ASA – Long term incentive programme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom